Novartis AG (NYSE:NVS – Free Report) – Analysts at Zacks Research lowered their Q1 2028 earnings estimates for shares of Novartis in a note issued to investors on Friday, September 25th. Zacks Research analyst Team now anticipates that the company will post earnings per share of $2.54 for the quarter, down from their previous forecast of $2.55. The consensus estimate for Novartis’ current full-year earnings is $8.87 per share. Zacks Research also issued estimates for Novartis’ FY2028 earnings at $10.69 EPS.
Other equities research analysts have also recently issued reports about the stock. JPMorgan Chase & Co. reaffirmed a “buy” rating on shares of Novartis in a report on Sunday, August 9th. Weiss Ratings reiterated a “buy (b)” rating on shares of Novartis in a research note on Friday, July 24th. Sanford C. Bernstein restated a “neutral” rating on shares of Novartis in a research note on Wednesday, July 22nd. The Goldman Sachs Group reaffirmed a “sell” rating on shares of Novartis in a research report on Monday, September 21st. Finally, Royal Bank Of Canada started coverage on shares of Novartis in a report on Tuesday, September 8th. They issued a “sector perform” rating on the stock. Six investment analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $148.40.
Novartis Trading Down 2.0%
Shares of Novartis stock opened at $142.75 on Tuesday. The stock has a market cap of $272.39 billion, a P/E ratio of 21.53, a P/E/G ratio of 2.82 and a beta of 0.45. Novartis has a 12-month low of $121.57 and a 12-month high of $170.46. The business’s 50 day moving average is $151.25 and its 200-day moving average is $151.00. The company has a quick ratio of 0.67, a current ratio of 0.86 and a debt-to-equity ratio of 0.89.
Novartis (NYSE:NVS – Get Free Report) last issued its quarterly earnings results on Tuesday, June 30th. The company reported $2.41 earnings per share (EPS) for the quarter. The firm had revenue of $14.95 billion for the quarter. Novartis had a net margin of 23.29% and a return on equity of 38.56%.
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Highland Investment Advisors LLC bought a new stake in shares of Novartis in the second quarter valued at about $25,000. Evolution Wealth Management Inc. increased its position in Novartis by 552.0% during the second quarter. Evolution Wealth Management Inc. now owns 163 shares of the company’s stock worth $26,000 after acquiring an additional 138 shares during the period. Atlatl Advisers LLC acquired a new stake in Novartis in the 2nd quarter worth about $26,000. Archer Investment Corp boosted its holdings in Novartis by 93.0% in the 1st quarter. Archer Investment Corp now owns 166 shares of the company’s stock valued at $25,000 after purchasing an additional 80 shares during the period. Finally, Silicon Valley Capital Partners grew its position in shares of Novartis by 519.4% during the 2nd quarter. Silicon Valley Capital Partners now owns 192 shares of the company’s stock worth $30,000 after purchasing an additional 161 shares in the last quarter. 13.12% of the stock is owned by institutional investors and hedge funds.
About Novartis
Novartis AG is a Switzerland-based pharmaceutical company focused on the discovery, development and commercialization of innovative medicines. The company’s research and commercial activities center on cardiovascular, renal and metabolic diseases, immunology, neuroscience, oncology and hematology. Its portfolio includes prescription medicines such as Entresto, Cosentyx, Kesimpta, Kisqali, Pluvicto, Leqvio and Jakavi, as well as other therapies for serious and chronic conditions.
Novartis serves patients and healthcare providers in markets worldwide, with operations spanning North America, Europe, Asia and other international regions.
Featured Articles
- Five stocks we like better than Novartis
- Deutsche Bank Makes a Contrarian Call on Netflix—What Does It Mean for Investors?
- O’Reilly Automotive’s Stock Slump Hides a Stronger Business
- McDonald’s Stock Slump Makes Its AI Pricing Bet Even Riskier
- Broadcom’s AI Growth Story Faces a $161 Billion Anthropic Test
Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.
